Advertisement

Ovarian Carcinoma: Tumor- and Molecular Biology

  • B. Kacinski
Part of the AGO Arbeitsgemeinschaft für Gynäkologische Onkologie book series (AGO)

Abstract

During the normal monthly ovulatory cycle, ovarian surface epithelium undergoes a set of changes including destruction, proliferation, and regeneration which is regulated by many (peptide and steroid) hormones and their receptors. The corresponding genes transduce receptor/ligand signals to alter DNA synthesis and gene expression. Point mutation, rearrangement, or deletions of chromosomal DNA sequences which alter the function and/or expression of these genes might sufficiently perturb normal ovarian epithelial cell proliferation and differentiation to produce benign, borderline, and invasively-ma- lignant neoplasms from normal surface epithelium.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Huber H., Knogler W., Karlic H., Akrad M. et al.: Structural chromosomal abnormalities in gynecologic malignancies. Cancer Genet Cytogenet 50: 189–197, 1990PubMedCrossRefGoogle Scholar
  2. 2.
    Eccles D.M., Cranston G., Steel C.M., Nakamura Y., Leonard R.C.: Allele losses on chromosome 17 in human epithelial ovarian carcinoma. Oncogene 5: 1599–1601,1990PubMedGoogle Scholar
  3. 3.
    Kopf I., Strid K.G., Islam M.Q., Granberg S. et al.: Heterochromatin variants in 109 ovarian cancer patients and 192 healthy subjects. Hereditas 113: 7–16, 1990PubMedCrossRefGoogle Scholar
  4. 4.
    Russell S.E., Hickey G.I., Lowry W.S., White P., Atkinson R.J.: Allele loss from chromosome 17 in ovarian cancer. Oncogene 5: 1581–1583, 1990PubMedGoogle Scholar
  5. 5.
    Gallion H.H., Powell D.E., Smith L.W., Morrow J.K. and others: Chromosome abnormalities in human epithelial ovarian malignancies. Gynecol. Oncol. 38: 473–477, 1990PubMedCrossRefGoogle Scholar
  6. 6.
    Roberts C.G., Tattersall M.H.: Cytogenetic study of solid ovarian tumors. Cancer Genet. Cytogenet. 48: 243–253, 1990CrossRefGoogle Scholar
  7. 7.
    Boltz E.M., Harnett P., Leary J., Houghton R. et al.: Demonstration of somatic rearrangements and genomic heterogeneity in human ovarian cancer by DNA fingerprinting. Br. J. Cancer 62: 23–27, 1990PubMedCrossRefGoogle Scholar
  8. 8.
    Bello M.J., Rey J.A.: Chromosome aberrations in metastatic ovarian cancer: relationship with abnormalities in primary tumors. Int. J. Cancer 45: 50–54, 1990PubMedCrossRefGoogle Scholar
  9. 9.
    Lee J.H., Kavanagh J.J., Wildrick D.M., Wharton J.T., Blick M.: Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas. Cancer Res. 50: 2724–2728, 1990PubMedGoogle Scholar
  10. 10.
    Zheng J.P., Robinson W.R., Ehlen T., Yu M.C., Dubeau L.: Distinction of low grade from high grade ovarian cancer on the basis of loss of heterozygosity on chromosomes 3, 6, 11 and HER2/neu gene expression. Cancer Res. in press, 1991Google Scholar
  11. 11.
    Bello M.J., Moreno S., Rey J.A.: Involvement of 9p in metastatic ovarian adenocarcinomas. Cancer Genet. Cytogenet. 45: 223–229,1990CrossRefGoogle Scholar
  12. 12.
    Ehlen T., Dubeau L.: Loss of heterozygosity on chromosomal segments 3p, 6q and lip in human ovarian carcinomas. Oncogene 5: 219–223,1990PubMedGoogle Scholar
  13. 13.
    Berchuck A., Davidoff A.M., Kearns B.J., Clarke-Pearson D.L., Iglehart J.D., Bast R.C., Marks J.R.: Overexpression and mutation of the p53 oncogene in ovarian cancer. Proceedings of the Society of Gynecologic Oncologists: 217,1991Google Scholar
  14. 14.
    Call K.M., Glaser T., Ito C.Y., Buckler A.J., et al.: Isolation of zinc finger polypeptide gene at chromosome 11 Wilm's tumor region. Cell 60: 509–520,1990PubMedCrossRefGoogle Scholar
  15. 15.
    Knyazev P.G., Nikiforova I.F., Serova O.M., Pluzhnikova G.F.: Distribution and rearrangements of alleles of c-Ha-ras-1 protooncogene and their correlation with the development of lung, ovarian and thyroid cancers. Neoplasma 37: 647–655,1990PubMedGoogle Scholar
  16. 16.
    Serova O.M., Nikiforova I.F., Iurkova L.E., Vinokurov V.L., Kniazev P.G.: Alterations of c-myc and c-Ha-ras-1 oncogenes in human ovarian cancer. Language: Rus.; Eksp. Onkol. 12:47–49,1990Google Scholar
  17. 17.
    Berchuck A., Olt G.J., Everitt L., Soisson A.P. et al.: The role of peptide growth factors in epithelial ovarian cancer. Obstet. Gynecol. 75: 255–262,1990PubMedGoogle Scholar
  18. 18.
    Naylor M.S., Malik S.T., Stamp G.W., Jobling T., Balkwill F.R.: In situ detection of tumour necrosis factor in human ovarian cancer specimens. Eur. J. Cancer 26: 1027–1030, 1990PubMedCrossRefGoogle Scholar
  19. 19.
    Malik S.T., Griffin D.B., Naylor M.S., Fiers W. et al.: The complex effects of recombinant tumour necrosis factor-alpha (rhTNF-alpha) in human ovarian cancer xenograft models. Prog. Clin. Biol. Res. 349: 393–403,1990PubMedGoogle Scholar
  20. 20.
    Janz J., Kohler M., Bauknecht T., Wagner E.: Growth control in gynecological tumor cell lines and tumor biopsies: significance of EGF-R state and effect of EGF and TGF-a on colony formation. Cancer J. 10: 323–330,1989Google Scholar
  21. 21.
    Marth C., Lang T., Koza A., Mayer I., Daxenbichler G.: Transforming growth factor-beta and ovarian carcinoma cells: regulation of proliferation and surface antigen expression. Cancer Lett. 51: 221–225,1990PubMedCrossRefGoogle Scholar
  22. 22.
    Kacinski B.M., Chambers S.K., Carter D., Filderman A.E., Stanley E.R.: The macrophage colony stimulating factor CSF-1, an auto- and paracrine tumor cytokine, is also a circulating »tumor marker« in patients with ovarian, endometrial and pulmonary neoplasms. Prog. Leuk. Biol. 10B: 393–400,1990Google Scholar
  23. 23.
    Kacinski B.M., Carter D., Mittal K., Yee L.D., Scata K.A., Donofrio L., Chambers S.K., Wang K.I., Yang-Feng T., Rohrschneider L.R. et al.: Ovarian adenocarcinomas express fms-complementary transcripts and fins antigen, often with coexpression of CSF-1. Am. J. Pathol. 137: 135–147,1990PubMedGoogle Scholar
  24. 24.
    Watson J.M., Sensintaffar J.L., Berek J.S., Martinez-Maza O.: Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res. 50: 6959–6965,1990PubMedGoogle Scholar
  25. 25.
    Kommoss F., Wintzer H.O., von Kleist S., Kohler M. et al.: In situ distribution of transforming growth factor alpha in normal human tissues in malignant tumours of the ovary. J. Pathol. 162: 223–230, 1990PubMedCrossRefGoogle Scholar
  26. 26.
    Bauknecht T., Kommoss F., Birmelin G., von Kleist S., Kohler M., Pfleiderer A.: Expression analysis of EGF-R and TGF-a in human ovarian carcinomas. Anticancer Res. 11: 1523–1528,1991PubMedGoogle Scholar
  27. 27.
    Bauknecht T., Kiechle M., Bauer G., Siebers J.: Characterization of growth factors in human ovarian carcinomas. Cancer Res. 46: 2614–2618,1986PubMedGoogle Scholar
  28. 28.
    Willman C.L., Stewart C.C., Miller V., Tao-Lin Y., Tomasi T.B.: Regulation of MHC class II gene expression in macrophages by hematopoietic colony-stimulating factors (CSF). J. Exp. Med. 170: 1559–1567,1989PubMedCrossRefGoogle Scholar
  29. 29.
    Rodriguez G.C., Berchuck A., Whitaker R.S., Schlossman D. et al.: Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am. J. Obstet. Gynecol. 164: 745–750,1991PubMedGoogle Scholar
  30. 30.
    Bauknecht T., Birmelin G., Kommoss F.: Clinical significance of oncogenes and growth factors in ovarian carcinomas. J. Steroid Biochem. Mol. Biol. 37: 855–862,1990PubMedCrossRefGoogle Scholar
  31. 31.
    Berchuck A, Rodriguez G.C, Kamel A., Dodge R.K., Soper J.T., Clarke-Pearson D.L., Bast R.C. Jr.: Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am. J. Obstet. Gynecol. 164: 669–674,1991Google Scholar
  32. Foekens J.A., van Putten W.L., Portengen H., Rodenburg C.J., Reubi J.C., Berns P.M., Henzen-Logmans S.C., van der Burg M.E.L., Alexieva-Figusch J., Klijn J.G.: Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-l-R) and somatostatin (SS-R) in patients with breast and ovarian cancer. J. Steroid Biochem. Mol. Biol. 37: 815–821,1990Google Scholar
  33. 33.
    Christen R.D., Horn D.K., Porter D.C., Andrews P.A., Mac Leod C.L., Hafstrom L., Howell S.B.: Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J. Clin. Invest. 86: 1632–1640,1990PubMedCrossRefGoogle Scholar
  34. 34.
    Bauknecht T., Angel P., Kohler M., Kommoss F., Birmelin G., Pfleiderer A., Wagner E.: Gene structure and expression analysis of EGF-R, TGF-a, Myc, Jun, Metallothionein in human ovarian carcinomas cancer accepted for publication. Oncogene 6: 941–952,1991Google Scholar
  35. 35.
    Baiocchi G., Kavanagh J.J., Talpaz M., Wharton J.T., Gutterman J.U., Kurzrock R.: Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. Cancer 67: 990–996,1991PubMedCrossRefGoogle Scholar
  36. 36.
    Kacinski B.M., Scata K.A., Carter D., Yee L.D., Sapi E., King B.L., Chambers S.K., Jones M.A., Pirro M.H., Stanley E.R., Rohrschneider L.R.: FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. Oncogene 6: 941–952,1991PubMedGoogle Scholar
  37. 37.
    Taylor H., Kacinski B.M., Kohorn E.I., Chambers S.K., Chambers J.T., Carter D., Scata K.A., Schwartz P.E.: A potential role for CSF-1 receptor, EGF-receptor, their ligands, and tyrosine kinases encoded by the trk and neu oncogenes in human cervical carcinomas. Proceedings of the Society for Gynecologic Investigation, 1990Google Scholar
  38. 38.
    Kacinski B.M., Stanley E.R., Carter D., Chambers J.T., Chambers S.K., Kohorn E.I., Schwartz P.E.: Circulating levels of CSF-1 (M-CSF), a lymphohematopoietic cytokine, may be a useful marker of disease status in patients with malignant ovarian neoplasms. Int. J. Rad. One. Biol. Phys. 17:159–164,1989CrossRefGoogle Scholar
  39. 39.
    Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., Press M.F.: Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712, 1988CrossRefGoogle Scholar
  40. 40.
    Berchuck A., Kamel A., Whitaker R., Kerns B. et al.: Overexpression of HER-2/NEU is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50:4087–4091,1990PubMedGoogle Scholar
  41. 41.
    Haidane J.S., Hird V., Hughes C.M., Gullick W.J.: c-erbB-2 oncogene expression in ovarian cancer. J. Pathol. 162: 231–237,1990CrossRefGoogle Scholar
  42. 42.
    Kacinski B.M., Mayer A.G., King B.L., Chambers S.K.: NEU oncogene protein overexpression in benign, borderline and malignant ovarian neoplasms. Gynecol. Oncol, in press, 1992Google Scholar
  43. 43.
    Baker V.V., Borst M.P., Dixon D., Hatch K.D. et al.: C-myc amplification in ovarian cancer. Gynecol. Oncol. 38: 340–342,1990PubMedCrossRefGoogle Scholar
  44. 44.
    Kacinski B.M., Carter D., Kohorn E.I., Mittal K., Bloodgood R.S., Donahue J., Kramer C.A., Fischer D., Edwards R., Chambers S.K., Chambers J.T., Schwartz P.E.: Oncogene expression in vivo by ovarian adenocarcinomas and mixed-mullerian tumors. Yale J. Biol. Med. 62: 379–392, 1989Google Scholar
  45. 45.
    Schreiber G., Dubeau L.: C-myc proto-oncogene amplification detected by polymerase chain reaction in archival human ovarian carcinomas. Am. J. Pathol. 137: 653–658,1990PubMedGoogle Scholar
  46. 46.
    Rubin S.C., Finstad C.L., Hoskins W.J., Saigo P.E., Provencher D.M., Federici M.G., Hakes T.B., Markman M., Reichman B.S., Lloyd K.O., Lewis J.L. Jr.: Expression of P- glycoprotein in epithelial ovarian cancer: Evaluation as a marker of multidrug resistance. Am. J. Obstet. Gynecol. 163: 69–73,1990PubMedGoogle Scholar
  47. 47.
    Perez P.R., Hamilton T.C., Ozols R.F.: Resistance to alkylating agents and cis-platin: insights from ovarian carcinoma model systems. Pharmacol. Ther. 48:19–27,1990PubMedCrossRefGoogle Scholar
  48. 48.
    Andrews P.A., Jones J.A., Varki N.M., Howell S.B.: Rapid emergence of acquired CDDP(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun. 2: 93–100,1990PubMedGoogle Scholar
  49. 49.
    Mann S.C., Andrew P.A., Howell S.B.: Short term CDDP(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemoth. Pharm. 25: 236–240,1990Google Scholar
  50. 50.
    Andrews P.A., Murphy M.P., Howell S.B.: Characterization of cis-platin resistant human ovarian carcinoma cells. Eur. J. Cancer 26: 1–23,1990CrossRefGoogle Scholar
  51. 51.
    Schilder R.J., Hall L., Monks A., Handel L.M., Fornace A.J. Jr., Ozols R.F., Fojo A.T., Hamilton T.C.: Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J. Cancer 45: 416–422,1990CrossRefGoogle Scholar
  52. 52.
    Katz E.J., Andrew P.A., Howell S.B.: The effect of DNA polymerase inhibitors of the cytotoxicity of cisplatin in human ovarian carcinoma cells. Cancer Commun. 2: 159–164, 1990PubMedGoogle Scholar
  53. 53.
    Lai G.M., Ozols R.F., Young R.C., Hamilton T.C.: Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J. Natl. Cancer Inst. 81: 535–539,1989PubMedCrossRefGoogle Scholar
  54. 54.
    Kashani-Sabet M., Wang W., Scanlon K.J.: Cyclosporin A suppresses cisplatin-induced c- fos gene expression in ovarian carcinoma cells. J. of Biol. Chem. 265: 11285–11288,1990Google Scholar
  55. 55.
    Isonishi S., Andrews P.A., Howell S.B.: Increased sensitivity to CDDP(II) in a human ovarian carcinoma cells in response to treatment with 12–0-tetradecanoylphorbol-13-acetate. J. Biol. Chem. 5: 3623–3627,1990Google Scholar
  56. 56.
    Gerhardt R.T., Perras J.P., Sevin B.U., Petru E. et al.: Characterization of in vitro chemo- sensitivity of perioperative human ovarian malignancies by ATP chemosensitivity assay. Am. J. Obstet. Gynecol. 165: 244–255,1991.Google Scholar
  57. 57.
    Petru E., Sevin B.U., Perras J., Boike G. et al.: Comparitive chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP bioluminescence. Gynecol. Oncol. 38: 155–160,1990PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • B. Kacinski

There are no affiliations available

Personalised recommendations